A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer

Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study ID
NCT07071714
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • SHR-8068 Injection — DRUG
    SHR-8068 injection.
  • Adebrelimab Injection — DRUG
    Adebrelimab injection.
  • Bevacizumab Injection — DRUG
    Bevacizumab injection.

Study Details

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-8068 injection in combination with anti-tumor therapies in subjects with colorectal cancer.

Key Dates

First listed
Jul 17, 2025
Start date
Jul 22, 2025
Status verified
Mar 2026
Primary completion
Oct 31, 2031
Completion
Oct 31, 2031

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Part A Group
  • Experimental: Part B Group

Primary Outcome Measure

Pathological Complete Response (pCR) [ Time Frame: About 7 months. ]

Central Contacts

Related Studies